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Abstract 
Background Type 2 diabetes mellitus (T2DM) is a signif-
icant global public health problem affecting more than 285 
million people worldwide. Over 70% of those with T2DM 
live in developing countries, and this proportion is 
increasing annually. Evidence suggests that lifestyle and 
other nonpharmacological interventions can delay and even 
prevent the development of T2DM and its complications; 
however, to date, programs that have been specifically 
adapted to the needs and circumstances of developing 
countries have not been well developed or evaluated. 
Purpose The purpose of this article is to review published 
studies that evaluate lifestyle and other non-pharmacological 
interventions aimed at preventing T2DM and its complica-
tions in developing countries. 
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Methods We undertook an electronic search of MEDLINE, 
PubMed, and EMBASE with the English language restric-
tion and published until 30 September 2009. 
Results Nine relevant publications from seven studies were 
identified. The reported interventions predominantly used 
counseling and educational methods to improve diet and 
physical activity levels. Each intervention was found to be 
effective in reducing the risk of developing T2DM in 
people with impaired glucose tolerance, and improving 
glycemic control in people with T2DM. 
Conclusions The current evidence concerning the preven-
tion of T2DM and its complications in developing countries 
has shown reasonably consistent and positive results; 
however, the small number of studies creates some 
significant limitations. More research is needed to evaluate 
the benefits of low-cost screening tools, as well as the 
efficacy, cost-effectiveness, and sustainability of culturally 
appropriate interventions in such countries. 
Keywords Type 2 diabetes . Complications . Prevention . 
Developing countries 
Introduction 
Type 2 diabetes mellitus (T2DM) is a significant global 
public health problem [1, 2]. The International Diabetes 
Federation recently reported that the number of people with 
diabetes will escalate from 285 million in 2010 to 438 
million by 2,030, with more than 70% of cases already 
from developing countries [2]. Despite a number of 
significant global and regional initiatives being undertaken 
to prevent diabetes and diabetes-related complications [3– 
7], seven out of the top ten countries with the greatest 
number of people living with diabetes are low- or middle-
income countries. These include China, India, Russia, 
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Brazil, Pakistan, Indonesia, and Bangladesh [8–11], with 
China now having the largest number of individuals with 
diabetes (92.4 million) in the world [8]. 
Each year, almost four million deaths are directly 
attributable to diabetes, constituting 6.8% of the total global 
(all-age and all-cause) mortality [12, 13]. Diabetes is the 
fourth leading cause of disease-related death and almost 
80% of diabetes-related deaths occur in developing 
countries. It has been projected that diabetes-related deaths 
will increase by 50% in the next 10 years if no urgent action 
is taken [14]. T2DM poses a significant economic burden to 
individuals, families, health systems, and nations, particular-
ly in resource-poor countries [14, 15]. Despite this, over 
80% of the world’s diabetes care-related expenditure occurs 
in developed countries [16]. Given the rapidly escalating 
financial and societal costs associated with diabetes care in 
developing countries, where resources to address the disease 
are severely limited, there is an urgent need for the 
development, implementation, and evaluation of programs 
to prevent T2DM and its complications [4]. 
Since the concept of T2DM prevention on a mass scale was 
first proposed early in the twentieth century [17], and was 
more recently emphasized by the World Health Organization 
(WHO) [18] and other international organizations, a number 
of very well-conducted intervention trials have now evalu-
ated the prevention of diabetes and its complications in 
developed countries. These trials include the Malmo Feasi-
bility Study in Sweden [19], the Finnish Diabetes Prevention 
Study (DPS) [20–22] and the US Diabetes Prevention 
Program (DPP) [23]; all of which have demonstrated 
comparable efficacy, by reducing the risk of developing 
T2DM by up to 63% in lifestyle intervention groups compared 
with controls. A recent systematic review and meta-analysis 
by Gillies et al. confirmed these findings, reporting that non-
pharmacological interventions were effective in reducing the 
risk of T2DM in people with impaired glucose tolerance (IGT) 
by up to 60% compared with control groups [24]. 
Trials focused on the prevention of T2DM complications 
conducted in developed countries have not directly examined 
the effects of non-pharmacological interventions on compli-
cation incidence. However, studies have demonstrated that 
non-pharmacological interventions are effective in reducing 
glycemic levels in people with T2DM [19, 20] and work from 
the UK and Japan indicates that optimal control of glycemic 
levels in people with newly diagnosed T2DM can reduce the 
development of complications [25, 26]. 
Despite the evidence concerning prevention of T2DM and 
its complications in developed countries, the translation of 
these programs to developing countries, where resources are 
limited to address the problem, still presents a very significant 
challenge. Therefore, it is important to develop and evaluate 
culturally appropriate interventions in developing countries 
[3, 27]. This paper reviews the study characteristics, efficacy, 
and cost-effectiveness of those non-pharmacological inter-
ventions aimed at preventing T2DM and its related compli-
cations in developing countries. 
Methods 
Search Strategy 
We undertook an electronic search of MEDLINE, PubMed, 
and EMBASE with the search terms “Diabetes Mellitus 
Type 2,” “Glucose Intolerance,” “Primary Prevention,” 
“Secondary Prevention,” “Diabetes Complications,” and 
“Lifestyle Intervention.” These search terms were com-
bined with the search term “Developing Countries” to 
identify relevant articles. In addition, we performed a 
search of policy and program documents developed by 
different national and international organizations. Further-
more, all relevant reference lists from the main papers were 
hand searched for additional papers of interest. The article 
search, inclusion and selection process is shown in Fig. 1. 
Inclusion Criteria 
The search was restricted to English language with papers 
published until 30 September 2009. We applied the World 
Bank 2008 classification criteria [28] to identify developing 
countries. Those studies/trials that employed lifestyle or 
non-pharmacological interventions conducted in developing 
countries with a glucose measure as a primary outcome 
were included. There was no restriction on sample size or 
duration of the intervention. 
Information Assessment 
Two independent reviewers examined each full-text paper 
for eligibility and extracted and tabulated all relevant 
information. Any differences were resolved by discussion 
and consensus with other authors. Inclusion or exclusion of 
the studies was determined by consensus between authors. 
The information assessment and synthesis were primarily 
based on the main findings of the publications. 
Results 
We initially identified 247 research articles by Medline, 
PubMed, and EMBASE searches. After a review of the 
titles and abstracts, 84 papers closely matched our inclusion 
criteria. The full papers were examined, however, 75 papers 
did not meet our inclusion criteria (i.e., evaluation of non-
pharmacological interventions aimed at prevention of the 
development of T2DM or its associated complications, the 
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Fig. 1 Flow chart showing 
articles search, inclusion criteria, 
and selection process 
Search engine: MEDLINE, PubMed and EMBASE searches 
Main search terms: 
“Diabetes Mellitus Type 2”, “Glucose Intolerance”, “Primary Prevention” 
“Secondary Prevention”, “Diabetes Complications”, “Lifestyle Intervention”, 
“Developing Countries” 
84 articles retrieved for more 
detailed evaluation (abstract 
+full articles examined) 
247 articles identified (title and 
abstract reviewed) 
163 papers excluded (on 
the basis of title and 
abstract, did not fulfil 
inclusion criteria) 
Inclusion criteria 
used: Lifestyle or non-
pharmacological 
interventions in 
developing countries 
published until 30 
September 2009. 
Written only in English 
language 
9 articles were included 
Prevention of the development 
of T2DM: 5 
Lifestyle management: 4 
Cost effectiveness: 1 
inclusion of blood glucose or glycosylated hemoglobin 
(HbA1c) as a primary outcome and the study being 
undertaken in a developing country), so they were subse-
quently excluded. Consequently, nine publications from seven 
studies were included in this review. A summary of each 
intervention and the findings are presented in this section. The 
main findings of the studies are divided into four subsections: 
(1) sample characteristics, (2) intervention or program 
characteristics, (3) effectiveness of the programs and (4) 
cost-effectiveness. The key sample characteristics and the 
findings of the study are summarized in Tables 1 and 2 and 
intervention characteristics in Tables 3 and 4. 
Sample Characteristics 
Prevention of the Development of T2DM Five relevant 
publications from three studies assessing effectiveness of 
the lifestyle interventions for prevention of the development 
of T2DM were identified. There was significant heteroge-
neity in the sample characteristics, such as sample size, age, 
inclusion criteria, type of sample, and length of follow-up, 
across the studies (Table 1). The Da-Qing study, a 
randomized controlled trial (RCT) designed to prevent 
diabetes progression in people with IGT in an urban area in 
China, recruited 283 men and 247 women over 25 years of 
age (mean age, 45±9.1 years) [29, 30]. The active 
intervention of this program lasted 6 years. The Indian 
75 were excluded 
Non-interventions: 31 
Conducted in developed 
countries: 24 
Reviews: 16 
Glucose measure was 
not primary outcome: 2 
Study protocol: 2 
Management of T2DM: 4 
Interpersonal education based: 2 
Cellular phone/ internet based: 2 
Diabetes Prevention Program (IDPP-1) was a 3-year 
prospective RCT that recruited an urban population aged 
35–55 years old with persistent IGT [31]. The sample of 
421 men and 110 women were leaner and yet more insulin 
resistant than the subjects included in the Finnish DPS [20– 
22] and US DPP [23] studies. A community-based diabetes 
prevention study by Balagopal et al., undertaken in rural 
India, recruited 703 villagers aged 10–92 years old [32]. 
The mean age of participants was 35.8±17.0 years and 
follow-up lasted 7 months. 
Blood Glucose Measurements and Criteria for Participant 
Selection in Studies to Prevent the Development of 
T2DM The Da-Qing and IDPP-1 studies used oral glucose 
tolerance tests to assess blood glucose levels. The Da-Qing 
study [29] implemented the WHO 1985 criteria [33] to  
survey and identify people with normoglycemia, impaired 
fasting glucose (IFG), IGT, and T2DM. The IDPP-1 [31] 
used the WHO 1999 criteria [34] and the community-based 
program in India [32] used a glucometer to measure blood 
glucose and the American Diabetes Association (ADA) 
criteria 2005 to classify IGT [35]. The WHO 1999 and the 
ADA 2005 use the same criteria for classifying people with 
diabetes, IGT and IFG, however, the WHO 1985 classifi-
cation included higher cut-off values for fasting and 2-h blood 
glucose levels compared with the later WHO 1999 and ADA 
2005 criteria. 
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Table 3 Summary of study intervention characteristics for prevention of development of T2DM 
Study/Ref Intervention characteristics Intensity, duration, and regularity 
Da-Qing, 
China 
[29, 30] 
IDPP-1, India 
[31, 40] 
Community 
based, India 
[32] 
Intervention groups—received individual/small-group counseling, 
delivered by trained physicians, nurses, and technicians 
Diet group—those with body mass index (BMI) of ≥25 kg/m2 
advised to lose weight, through goal setting on healthy diets. 
Those with BMI of <25 kg/m2 encouraged to eat healthy diets 
with prescribed proportions of carbohydrates, fat, and protein 
Exercise group—advised to increase amount of leisure time physical exercise 
Diet+exercise group—received both interventions as above 
Control group—received usual care (general information on diabetes/IGT, 
brochures containing information on improving diet/physical activity) 
Intervention groups—received individual counseling, followed up by telephone 
Lifestyle group—those performing “moderate” activity (physical labor/walk or 
cycle for >30 min/day/perform exercise regularly) advised to continue 
routine activities. Those performing sedentary/light physical activity 
advised to walk briskly for ≥30 min/day 
Advice on diet modification given, including reduction in total calories and 
refined carbohydrates/fats, avoidance of sugar, and inclusion of fiber-rich foods 
Metformin group—received metformin tablets for 3 months and 
provided diaries to record daily intake of tablets 
Lifestyle+metformin group—received both interventions as above 
Control group—received advice on standard healthcare 
Individual face-to-face culturally sensitive (Tamil language) educational sessions 
on dietary modification (increasing fiber, reducing fat, portion control), increasing 
physical activity, and relaxation breathing techniques conducted 
Group events, such as cooking/physical activity demonstrations, 
organized as reinforcement 
1 individual counseling session 
Weekly small-group counseling 
sessions 
for 1 month, monthly for 3 months 
and then once every 3 months 
1 individual counseling at the 
beginning of the study 
Telephonic contact after 
2 weeks or by letter 
Monthly telephonic contacts personal 
sessions at 6 monthly intervals 
10 face-to-face individual education 
sessions 
Group events for reinforcement 
Additional counseling sessions for 
individuals with impaired FBG 
Prevention of Diabetes Complications Four relevant studies 
assessing effectiveness of lifestyle interventions for the 
prevention of diabetes complications were identified. The 
sample characteristics of the intervention studies preventing 
the development of complications in people with T2DM 
were heterogeneous (Table 2). One RCT conducted in 
China aimed at improving glycemic control among over-
weight people with diabetes recruited 150 individuals, with 
100 in the intervention arm and 50 in the control group 
[36]. With a mean age of 51±1.0 years, this sample was 
followed up for 6 months. A hospital-based RCT in 
Thailand recruited 147 adults over 35 years of age [37]. 
This follow-up lasted 6 months. Of the two RCTs 
conducted in Korea, one recruited 51 patients [38] and the 
other 34 patients with T2DM [39], each with a mean age of 
47 years. The first sample was followed up over 3 months 
and the second over 6 months. 
Intervention Characteristics 
Prevention of the Development of T2DM The three studies 
undertaken to prevent the development of T2DM in 
developing countries included a range of interventions 
(Table 3). The Da-Qing study comprised three lifestyle 
intervention groups (diet, exercise, and diet+exercise), with 
one control group [29]. Overweight participants were 
advised to improve healthy food habits and increase 
physical activity through individual and small-group ses-
sions, until they had reached a target body mass index of 
23 kg/m2. The IDPP-1 included a lifestyle intervention, 
medication (metformin tablets) group, combined lifestyle 
and metformin group and control group [31]. Participants in 
the lifestyle intervention group received individual advice 
regarding diet modification and exercise promotion. The 
intervention by Balagopal et al. comprised an educational 
intervention for the rural community; however, no control 
condition was included [32]. Culturally sensitive and 
linguistically appropriate sessions on dietary modification, 
physical activity, and simple relaxation breathing techni-
ques constituted the main components of this intervention. 
Prevention of Diabetes Complications There was a signifi-
cant variation in the interventions employed across the four 
studies aimed at preventing T2DM complications in devel-
oping countries (Table 4). Two studies included an educa-
tional intervention [36, 37] and two involved telemedicine-
based nurse-led educational intervention [38, 39]; all with 
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Table 4 Summary of study intervention characteristics for prevention of complications 
Study/Ref Intervention characteristics Intensity, duration, and regularity 
Sun et al., 
China [36] 
Wattana et al., 
Thailand [37] 
Kim, 
Korea [38] 
Kim and Song, 
Korea [39] 
Intervention group—received monthly group sessions on diabetes management/ 
lifestyle modification delivered by an experienced nutritionist 
Participants received weekly consultation sessions on diet and medical 
evaluations including assessment of adverse events, review of blood 
glucose measurements and adjustment of medications 
Participants were provided with blood glucose monitors 
Control group—received monthly group sessions providing diabetes education 
Intervention group—participated in small-group diabetes education classes 
(120 min) and discussions (90 min) 
Received individual home visits from researcher (45 min) and 
patient education manual 
Participants were taught how to make lifestyle changes, monitor symptoms, 
record, and interpret their blood glucose levels, blood pressure, and blood 
lipid levels 
Control group—received usual nursing care, health education during waiting 
time at hospital and diabetes education class at the end of the study 
Intervention group—received education and reinforcement on diet, exercise, 
medication adjustment, and frequent self-monitoring of blood 
glucose levels led by nurse via mobile phones and internet 
Participants were provided with blood glucose monitors 
Control group—met an endocrinologist once or twice during a 3-month study 
Those in control group who visited program intervention center received advice 
on medication, medication dosage, and lifestyle modification from 
endocrinologist 
Intervention group—received education and reinforcement on diet, exercise, 
medication adjustment, and frequent self-monitoring of blood glucose 
levels led by nurse via mobile phones and internet 
Participants were provided with blood glucose monitors 
Control group—met an endocrinologist 2–4 times during a 6-month study 
Those in control group who visited program intervention center received advice 
on medication, medication dosage, and lifestyle modification from 
endocrinologist 
Weekly individual consultation sessions 
(30 min each) for 6 months 
Additional monthly group sessions 
1 small-group diabetes education class, 
followed by 4 small-group discussions 
2 individual home visit sessions in 
6 months 
Weekly individual sessions via cellular 
phone and Internet for 6 months 
Weekly individual sessions via cellular 
phone or wired Internet for 3 months 
comparison control groups. The educational interventions 
provided information on behavioral and lifestyle change. In 
one study, individuals in the intervention group received 
monthly group sessions on the management of diabetes and 
lifestyle modification delivered by an experienced nutrition-
ist [36]. This group also received weekly consultation 
sessions on diet and medical evaluation. In comparison, the 
control group received monthly group sessions comprising 
diabetes education. In another study, individuals in the 
intervention group participated in small-group diabetes 
education classes and received a patient education manual 
[37]. A researcher also conducted home visit sessions for 
each of these participants. The control group, in contrast, 
received usual nursing care before they began diabetes 
education classes at the end of the study. The two 
telemedicine-based nurse-led educational interventions com-
prised education and reinforcement of healthy diet, physical 
exercise, and medication adjustment to those participants in 
the intervention groups [38, 39]. The reminders for frequent 
self-monitoring of blood glucose levels were sent to each 
participant in the intervention groups, using short message 
services via cellular mobile phone. 
Intervention Effectiveness 
Prevention of the Development of T2DM Each study 
showed significant reductions in the development of 
T2DM in the intervention group compared with controls. 
The Da-Qing study successfully reduced the risk of 
developing T2DM up to 46% in the lifestyle intervention 
group compared with the control group [29]. The 20-year 
follow-up showed that the group-based lifestyle interven-
tion implemented over 6 years prevented or delayed 
diabetes for up to 14 years, although the long-term effects 
on reduced cardiovascular disease morbidity and mortality 
were less clear [30]. The IDPP-1 reported high rates of 
progression of IGT to T2DM in control participants (18.3% 
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incidence per year), while both lifestyle modification and 
medication reduced T2DM incidence, with a relative risk 
reduction of 28.5% and 26.4%, respectively, over the 3-year 
study [31]. Interestingly, the IDPP-1 program did not show 
an additional benefit of combined lifestyle intervention and 
medication. The community-based, non-pharmacological 
diabetes prevention program in rural India was successful 
in reducing fasting blood glucose levels in adults with IFG 
by 11%, in youths by 17%, and in adults with T2DM by 
25% over the 7-month study, although the numbers in each 
group were small [32]. In addition, the authors reported 
improvements in obesity parameters and dietary intake. 
Prevention of Diabetes Complications Significant improve-
ments were observed in glycemic control across the range 
of diabetes complications prevention studies. One RCT in 
China improved glycemic control and markers of cardio-
vascular health in people with T2DM [36]. This program 
reduced HbA1c levels by 0.8% in the intervention group, 
compared with an elevation of 0.1% in the reference group 
over the 6-month study timeframe. Participants in both the 
intervention and reference groups achieved modest weight 
loss of 3.7% and 2.5%, respectively. The hospital-based 
RCT in Thailand demonstrated the efficacy of educational 
interventions by reducing HbA1c levels by 0.68% in the 
intervention group, compared with 0.07% in the control 
group over 6 months [37]. The program also demonstrated 
reductions in risk factors for coronary heart disease of 
4.83% in the intervention group, as opposed to 1.54% in 
the control group. Similarly, the two RCTs conducted in 
Korea showed reductions in HbA1c levels in adults with 
T2DM [38, 39]. One demonstrated reduced HbA1c levels 
of 1.15% in the intervention group compared with an 
elevation of 0.07% in the control group over 3 months [38, 
39], and the other reduced HbA1c levels by 1.09% in the 
intervention group, compared with no changes in the 
control group over the 6-month study [38, 39]. 
Cost-effectiveness 
Prevention of Development of T2DM The economic eval-
uation of the IDPP-1 was the only cost-effectiveness study 
of a diabetes prevention intervention program identified in 
a developing country [40]. This work concluded that the 
lifestyle intervention was cost-effective for preventing 
diabetes among high-risk individuals. The total cost spent 
to identify one subject with IGT was the equivalent of US 
$117. The total direct medical cost of the intervention in 
different groups over the 3-year intervention period was US 
$61 per subject in the control group, US $225 with lifestyle 
modification and US $270 with the lifestyle modification+ 
medication group. The cost of the intervention to prevent 
one case of diabetes was US $1,052 with lifestyle modifica-
tion and US $1,359 with lifestyle modification+medication. 
In addition, the number of individuals needed to treat to 
prevent a case of diabetes was 6.4 with lifestyle modification 
and 6.5 with lifestyle modification+medication. 
Prevention of Development of Complications No cost-
effectiveness studies for preventing T2DM complications 
in developing countries were identified. 
Discussion 
Diabetes in developing countries contributes to an increas-
ing proportion of the total global burden of diabetes [2, 14, 
41]. Prevention studies have now been conducted in China 
[29, 30, 36], India [31, 32, 40], Thailand [37], and Korea 
[38, 39]. Despite the limited number of studies, these 
studies do provide some important information concerning 
the efficacy and cost-effectiveness of non-pharmacological 
interventions for the prevention of T2DM and its related 
complications in developing countries. 
Prevention of the Development of T2DM 
The non-pharmacological interventions in China [29, 30] 
and India [31, 32] have demonstrated that the lifestyle 
interventions can result in significant reductions of risk for 
the development of T2DM in people with IGT or IFG. The 
Da-Qing study and the IDPP-1 each reported a significant 
relative risk reduction in the development of T2DM in the 
intervention groups, however these were substantially lower 
than shown in similar trials conducted in developed 
countries, including the Finnish DPS [20–22] and US 
DPP [23]. These latter trials have reported a relative risk 
reduction of 58% in diabetes incidence in the lifestyle 
intervention groups over approximately 3-year intervention 
periods. The lifestyle interventions in these trials focused 
on weight loss, intake of healthy diet, and promoting 
modest physical activity, and were delivered by a nutrition-
ist [20] and special educators (“case managers”) [23]. 
Although the risk reduction was lower in the developing 
countries, the progression of T2DM incidence in the control 
group was observed to be greater in the IDPP-1 [31] than in 
developed countries (IDPP-1 at 18.3% compared with DPS 
at 6% [42] and DPP at 11% per year [23]). Therefore, any 
reduction in the progression of T2DM in developing 
countries is particularly important. There are likely to be 
numerous explanations for the higher effectiveness in 
developed countries compared with low-income countries. 
For example, the existing structure of healthcare systems in 
developed countries provides a framework for effective 
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intervention studies [43]. Access to healthcare services is 
likely to be another important factor, as is the reduced level 
of health literacy in some developing countries. Poor 
adherence to standard diabetes care may be lower in 
developing countries as a result of competing priorities that 
are not present in developed countries. 
It is interesting to note that, even in samples with 
comparable age ranges and obesity levels, Indian cohorts 
demonstrated an elevated progression rate of T2DM 
compared with Chinese groups [29]. High prevalence of 
diabetes and elevated levels of insulin resistance in South 
Asian populations [44] could have resulted in the observed 
high rates of T2DM incidence in the control group in the 
Indian sample. The China Da-Qing intervention [29, 30] 
was reported to be more effective than the IDPP-1 [31]. The 
increased intensity and the mode of intervention delivery 
through trained physicians and nurses in the China Da-Qing 
study are likely to have influenced these differences. In 
terms of features of the interventions with higher efficacy, 
the inclusion of exercise, either alone or in conjunction with 
diet [29–32], demonstrated the greatest improvements in 
risk reduction of diabetes. 
Prevention of Diabetes Complications 
Maintaining glycemic control, in particular HbA1c levels 
lower than 7% [45–47], is important for preventing 
diabetes-related complications. Early effective intervention 
for the management of hyperglycemia, hypertension, and 
dyslipidemia can reduce the risk of developing diabetes-
related complications [48]. The non-pharmacological edu-
cational interventions in China [36], Thailand [37], and 
Korea [38, 39] demonstrated reductions of HbA1c levels 
and other cardiovascular disease risk factors, which might 
facilitate improvements in diabetes control and prevent 
disease-related complications. These findings are supported 
by other studies conducted in developed countries, which 
have resulted in reduced HbA1c levels, adiposity, and 
blood pressure in the intervention compared with control 
groups [25, 26, 49]. For example, a diabetes education and 
self-management program reduced HbA1c levels by 1.49% 
in people with newly diagnosed diabetes [25], and a weight 
reduction and exercise program for older African-American 
adults reduced HbA1c levels by 1.1% in the intervention 
compared with control groups [26]. Telehealth-delivered 
educational interventions in developing countries were also 
shown to be effective in reducing HbA1c levels in adults 
with T2DM [38, 39]. Previous work from developed 
countries has found similar results, demonstrating de-
creased HbA1c levels in patients receiving telephone-
based nurse support programs [50–52]. 
The interventions conducted in developed countries that 
focused on prevention of diabetes-related complications 
[25, 26, 49–52] have shown greater improvements in 
glycemic control compared with those in developing 
countries [36–39] (reduction of HbA1c level 0.9–1.7% 
compared with 0.7–1.1%). As discussed in the earlier 
paragraph in relation to primary prevention, there are 
multiple explanations for lower efficacy of such trials in 
developing countries compared with developed countries. 
In addition, within the studies in developing countries, the 
telehealth-delivered educational interventions [38, 39] 
reported greater reductions in HbA1c compared with those 
with interpersonal education-based programs [36, 37]. It is 
possible that the delivery of the interventions via trained 
nurses in the telehealth studies had an impact on the 
differentials in efficacy across these studies. 
Previous studies have shown that, in addition to 
lifestyle interventions, pharmacological interventions are 
effective in the prevention of diabetes-related complica-
tions [53–58]. The UKPDS, one of the most widely 
known studies, showed that anti-hypertensive medications 
reduced macrovascular endpoints by 37% and diabetes-
related mortality by 32% [53]. Similarly, a Danish study 
conducting a multifactorial intervention, implementing 
behavioral modification alongside pharmacological thera-
py, found CVD risk reductions of up to 50% in the 
intervention compared with the conventional treatment 
group [57]. Although the studies included in this review 
did not implement pharmacological interventions, other 
studies from low- and middle-income countries have 
shown similar results to those from the developed world 
with medication therapy within their programs [59–62]. 
Therefore, the existing evidence indicates that the use of 
medication is also important in the management of 
diabetes and preventing the related complications. 
Cost-effectiveness of Programs 
The 3-year IDPP-1 confirmed that a non-pharmacological 
intervention was cost-effective for preventing diabetes 
among high-risk Indian adults [40]. All the costs incurred 
in the different intervention groups of IDPP-1 were 
substantially lower and more cost-effective than the costs 
incurred in the US DPP [63], where the placebo group cost 
US $218, the lifestyle intervention group cost US $2,919 
and medication group cost US $2,681 over the 3-year 
intervention period. Sparse data are available examining the 
costs and cost-effectiveness of the interventions related to 
prevention of T2DM and its complications, and the studies 
that do exist come predominantly from developed countries 
[19, 63–65]. However, the cost and the cost-effectiveness 
estimations from the IDPP-1 study suggest that non-
pharmacological interventions for the prevention of 
T2DM in developing countries are, in absolute terms, 
cheaper and more cost-effective compared with studies 
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from the developed world, such as the DPP [63]. This 
evidence should encourage other developing countries to 
develop and implement cost-effective, non-pharmacological 
interventions to stem the escalating problem of T2DM and 
diabetes-related complications. 
Limitations of the Studies/Programs 
Prevention of the Development of T2DM The two Indian 
studies [31, 32] and  the Da-Qing  [29] study have some 
important limitations. Most importantly, these studies 
identified high-risk individuals using IGT or IFG classi-
fications, which employ relatively expensive screening 
methods that require individuals to fast and undergo 
blood tests. In countries such as China and India, where 
rates of diabetes are extremely high, it is not feasible or 
cost-effective to screen everyone using such expensive 
screening methods for diabetes. Low-cost screening 
methods such as short questionnaires to identify high-
risk individuals need to be developed and tested in 
diabetes prevention programs. Furthermore, in the IDPP-1, 
only one fifth of the subjects were female [31]; yet, the 
number of males and females in India with IGT are 
comparable [2, 9]. In addition, this program selected a 
sample from a middle class working people with persistent 
IGT in an urban setting; however it did not include people 
from rural areas, where two thirds of the population of 
India live, so generalizability to the whole population is 
problematic. Although the IDPP-1 estimated the direct 
medical costs and cost-effectiveness of the program [40], 
it did not estimate the longer-term cost-effectiveness of the 
program and the indirect costs which are often many times 
higher than the direct medical costs. The study by 
Balagopal et al. did not include a control group, comprised 
very small numbers of high-risk participants, and lacked 
sufficient follow-up (7 months) to determine the sustained 
effect of the intervention [32]. The Da-Qing study 
achieved a longer-term follow-up; however, it did not 
report the estimated cost and cost-effectiveness of the 
program [29, 30]. 
Prevention of Diabetes Complications A major limitation of 
these studies was the short follow-up periods, which varied 
between 3 [38] and 6 months  [36, 37, 39]. This meant the 
sustainability of the intervention effects could not be 
evaluated [36–39]. The time frame did not allow an 
evaluation of the efficacy of the trials on incidence of 
complications, only the observation of reduced risk factors 
associated with the development of complications. In 
addition, the hospital-based study in China had a large 
discrepancy in the number of participants in the control and 
intervention groups [36]. The two Korean RCTs included 
sample sizes (n=51 and 34) that were too small to reliably 
establish intervention effects, particularly over the short 
follow-ups of 3 and 6 months, respectively [38, 39]. 
Future Directions 
Given the escalating burden of noncommunicable diseases 
in low- and middle-income countries [66], research must 
begin to focus more heavily on effective chronic disease 
interventions [43]. Future programs to prevent diabetes and 
its associated complications in developing countries should 
focus on the appropriate development, adaptation, and 
implementation of efficacious, cost-effective intervention 
methods from developed and developing countries. 
However, it is also important to evaluate programs that 
combine more traditional educational and behavioral 
methods with peer support, telehealth, and other more 
contemporary approaches that are now being widely 
utilized around the world [67–72]. To date, diabetes 
prevention trials in developed as well as developing 
countries have primarily targeted those people with 
diagnosed pre-diabetes [20, 23, 29, 31]; however, in 
resource-constrained settings, it is not feasible to rely on 
the identification of such high-risk individuals using blood 
tests so the development of valid and reliable self-report 
risk assessment tools is also required [73]. In addition, it is 
very important to develop linguistically appropriate and 
context-specific lifestyle interventions that are tailored to 
meet the cultural, religious, and socioeconomic needs of 
the target communities, with long-term implementation to 
enable the sustainability of the targeted intervention 
outcomes. 
It is also necessary to consider the development and 
evaluation of programs that link with local community 
resources, relevant non-government organizations, and in 
particular, local health services. Interventions focused on 
chronic disease prevention and management in developing 
countries must engage healthcare systems to initiate the 
improvements and reform that are urgently required to 
support the long-term primary and secondary prevention 
and care of those at risk and with these diseases [43]. 
Conclusions 
We conclude that, despite the escalating burden of 
T2DM in developing countries, the current evidence 
concerning the prevention of T2DM and its complica-
tions in these countries still remains quite limited. 
Nevertheless, there is an urgent need to stem the growing 
epidemic of T2DM in rapidly developing countries that 
face significant resource constraints. This must be 
achieved by linking a significant primary prevention 
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effort in all countries with the use of low-cost behavioral 
medicine and related approaches to screen and identify 
high-risk individuals, followed by the development, 
implementation, and evaluation of community-based 
programs that are culturally relevant and cost-effective. 
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